Latest News Releases 10 April

A new autonomous drone system could provide ecologists with deeper insights into animal behavior in the wild, a study suggests.

A major study presented today at ESCMID Global 2025 has revealed that adults with respiratory syncytial virus-associated acute respiratory infection (RSV-ARI) face a 2.7-fold higher risk of death within one year compared to the general population.¹

Longest international trial on the effects of tirzepatide on weight in 700 adults with overweight or obesity and prediabetes reveals three distinct patterns of weight loss trajectories, with patients losing on average 10%, 20%, and 30% of their body weight after 3 years.

Women and those without obesity-related complications were more likely to achieve greater weight loss and hit weight-loss plateau later.

Findings suggest most adults taking tirzepatide stop losing weight in the first 6 months and then maintain weight-loss.

*Note – this is an early press release from the European Congress on Obesity in Malaga, Spain, 11-14 May. Please credit the congress when using this research*

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least 3 years in adults with overweight or obesity who do not have diabetes, according to new research being presented at this year’s European Congress on Obesity (ECO) in Malaga, Spain (11-14 May). The findings also indicate that females and those without obesity-related complications may be more responsive to tirzepatide treatment.

*Note – this is an early press release from the European Congress on Obesity in Malaga, Spain, 11-14 May. Please credit the congress when using this research.*

New research to be presented at this year’s European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that around two thirds of participants of the SURMOUNT-1 trial had only regained 5% or less of their so-called nadir (or lowest weight) three years after beginning treatment with tirzepatide. The study is by Professor Louis Aronne, Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York, NY, USA, and co-authors from Eli Lilly and Company, Indianapolis, IN, USA, which funded the study.

A pioneering study presented today at ESCMID Global 2025 has uncovered the potential of interleukin-6 (IL-6) as a powerful diagnostic biomarker for the early detection of sepsis in high-risk patient groups, including neonates, children and pregnant women. This study is the first to evaluate IL-6’s diagnostic performance in a real-world cohort across all three populations.¹

New research recently published in Archives of Sexual Behavior suggests children’s gender biases can be reflected in their facial emotional expressions.   

Psychology professor Doug VanderLaan and his colleagues at the University of Toronto Mississauga, studied 296 children (148 boys and 148 girls) in Canada between the ages of four and nine years old while Wang Ivy Wong, Karen Kwan and their colleagues at the Chinese University of Hong Kong, and The Hong Kong Polytechnic University studied 309 children (155 boys and 154 girls) in Hong Kong. All children watched four short stories that included five illustrations with pre-recorded audio narratives. The stories were presented in random order and showed peers who were in the same grade as the participant and displayed behaviours that either did or did not follow gender stereotypes. While viewing the stories, FaceReader software was used to code the intensities of participants’ emotions, including angry, disgusted, happy, sad, scared, and surprised.